Nicolas Meyer
Overview
Explore the profile of Nicolas Meyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
293
Citations
7868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andreu G, Boudjedir K, Meyer N, Carlier M, Drouet C, Py J, et al.
Transfus Med Rev
. 2025 Feb;
39(1):150875.
PMID: 39919322
Since 1998, leuko-reduction is used in France for all platelet concentrates (PCs), apheresis-derived (APCs) and pooled whole blood-derived buffy-coats (BCPCs). Platelet additive solutions (PAS), introduced in 2005, accounted for over...
2.
Doffoel M, Chaffraix F, Chahard A, Gras D, Bonomi O, Bildstein C, et al.
PLoS One
. 2025 Jan;
20(1):e0316158.
PMID: 39883611
The aim of this study was to determine the prevalence of advanced hepatic fibrosis and to individualize using Bayesian analysis its associated risk factors in patients with metabolic dysfunction-associated steatotic...
3.
Dummer R, Robert C, Scolyer R, Taube J, Tetzlaff M, Menzies A, et al.
Nat Med
. 2025 Jan;
31(1):144-151.
PMID: 39775043
Neoadjuvant immunotherapies have shown antitumor activity in melanoma. Substudy 02C of the global, rolling-arm, phase 1/2, adaptive-design KEYMAKER-U02 trial is evaluating neoadjuvant pembrolizumab (anti-PD-1) alone or in combination, followed by...
4.
Mroueh A, Algara-Suarez P, Fakih W, Gong D, Matsushita K, Park S, et al.
Cardiovasc Res
. 2024 Dec;
PMID: 39739876
Aims: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) show a cardioprotective effect in heart failure and myocardial infarction, pathologies often associated with low-grade inflammation. This cross-sectional study aims to investigate whether low-grade...
5.
Barret L, Liaigre L, Hlavaty A, Giai J, Laporte S, Ollier E, et al.
J Clin Epidemiol
. 2024 Dec;
179():111651.
PMID: 39724990
Objectives: To describe the priors and decision thresholds in phase 2 and 3 randomized controlled trials (RCTs) evaluating drug efficacy using Bayesian methods. Study Design And Setting: A systematic review...
6.
Basset-Seguin N, Djermane M, Herms F, Dalac S, Dereure O, Beylot-Barry M, et al.
J Eur Acad Dermatol Venereol
. 2024 Dec;
PMID: 39676714
No abstract available.
7.
Roncalli J, Roubille F, Meyer N, Pompilio G, Leroux L, Henon P, et al.
ESC Heart Fail
. 2024 Dec;
PMID: 39676512
Aims: The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+...
8.
Caillard S, Meyer N, Solis M, Bertrand D, Jaureguy M, Anglicheau D, et al.
Kidney Int
. 2024 Nov;
107(2):338-347.
PMID: 39490986
The MTOR inhibitors have demonstrated antiviral properties, and prior non-randomized studies have suggested they may have a suppressive effect on BKPyV replication. Here, in this randomized, multicenter, controlled trial (BKEVER...
9.
Falchero L, Meyer N, Molinier O, Al Freijat F, Pegliasco H, Lecuyer E, et al.
Eur J Cancer
. 2024 Aug;
210:114277.
PMID: 39168000
Background: The KBP studies are real-life nationwide, prospective, multicenter cohort studies of patients diagnosed with primary lung cancer that have been conducted in French non-academic public hospitals each decade since...
10.
Goichot B, Lefebvre F, Vinzio S, Cailleux A, Kuhn J, Schneegans O, et al.
Eur Thyroid J
. 2024 Aug;
PMID: 39159264
Objective: Subclinical hyperthyroidism (SCH) is common and associated with atrial fibrillation (AF) risk in the elderly. Current guidelines rely on a low level of evidence. Methods: Randomized clinical trial including...